Crinetics Pharmaceuticals Inc (CRNX)
44.79
+1.32
(+3.04%)
USD |
NASDAQ |
Jun 28, 16:00
44.71
-0.08
(-0.18%)
After-Hours: 20:00
Crinetics Pharmaceuticals Cash from Financing (Quarterly): 393.57M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 393.57M |
| December 31, 2023 | 37.92M |
| September 30, 2023 | 337.88M |
| June 30, 2023 | 12.66M |
| March 31, 2023 | 0.484M |
| December 31, 2022 | 0.115M |
| September 30, 2022 | 1.076M |
| June 30, 2022 | 118.99M |
| March 31, 2022 | 1.78M |
| December 31, 2021 | 163.86M |
| September 30, 2021 | 15.46M |
| June 30, 2021 | 73.30M |
| March 31, 2021 | 0.057M |
| December 31, 2020 | 0.097M |
| September 30, 2020 | -0.158M |
| Date | Value |
|---|---|
| June 30, 2020 | 108.15M |
| March 31, 2020 | 6.482M |
| December 31, 2019 | 0.017M |
| September 30, 2019 | 0.022M |
| June 30, 2019 | 0.008M |
| March 31, 2019 | 0.02M |
| December 31, 2018 | 0.009M |
| September 30, 2018 | 107.19M |
| June 30, 2018 | -0.513M |
| March 31, 2018 | 63.51M |
| December 31, 2017 | 7.071M |
| September 30, 2017 | -0.01M |
| June 30, 2017 | 4.711M |
| March 31, 2017 | 0.051M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.158M
Minimum
Sep 2020
393.57M
Maximum
Mar 2024
63.59M
Average
4.131M
Median
Cash from Financing (Quarterly) Benchmarks
| Syndax Pharmaceuticals Inc | 2.168M |
| NovaBay Pharmaceuticals Inc | -0.597M |
| Palatin Technologies Inc | 9.136M |
| iBio Inc | 5.025M |
| Theriva Biologics Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -52.86M |
| Cash from Investing (Quarterly) | 0.309M |
| Free Cash Flow | -184.45M |
| Free Cash Flow Per Share (Quarterly) | -0.7496 |
| Free Cash Flow to Equity (Quarterly) | -54.19M |
| Free Cash Flow Yield | -6.57% |